Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

SOUTH SAN FRANCISCO, Calif., May 21, 2024 -- Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment...

Related Keywords

United States ,California ,American ,Jonathang Goldin ,Martinl Decaris ,Christopher Keenan ,Los Angeles ,Gregoryp Cosgrove ,Drug Administration ,American Thoracic Society ,International Conference ,Pliant Therapeutics Inc ,European Medicines Agency ,Corporate Communications ,David Geffen School Of Medicine ,Clinical Development At Pliant Therapeutics ,Linkedin ,Development For Idiopathic Pulmonary Fibrosis ,Nasdaq ,Facebook ,University Of California ,Translational Sciences At Pliant ,Youtube ,Chief Medical Officer ,Dual Selective Inhibitor ,Idiopathic Pulmonary Fibrosis ,Primary Sclerosing ,Vice President ,Clinical Development ,Pliant Therapeutics ,Specific Cell Types ,Fibrotic Human ,Principal Scientist ,Interstitial Lung Disease Progression ,Senior Director ,Translational Sciences ,Quantitative Imaging ,Biomedical Physics ,David Geffen School ,Fast Track Designation ,Orphan Drug Designation ,Media Contact ,Investor Relations ,